deltatrials
Completed PHASE2 NCT00031694

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

A Phase II Study of Sequential Paclitaxel and Bryostatin-1 for Patients With Advanced Pancreatic Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Acinar Cell Adenocarcinoma of the Pancreas Duct Cell Adenocarcinoma of the Pancreas Recurrent Pancreatic Cancer Stage III Pancreatic Cancer Stage IV Pancreatic Cancer
Interventions bryostatin 1 paclitaxel
Updated 9 times since 2017 Last updated: May 18, 2021 Started: Mar 31, 2002 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

Listed as NCT00031694, this PHASE2 trial focuses on Acinar Cell Adenocarcinoma of the Pancreas and Duct Cell Adenocarcinoma of the Pancreas and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 9 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Mar 2021 — Sep 2021 [monthly]

    Completed PHASE2

▶ Show 4 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • The Bronx, United States